Harvard Apparatus Regenerative Technology Inc. (HRGN)
OTCMKTS · Delayed Price · Currency is USD
2.350
+0.050 (2.17%)
At close: Sep 3, 2026
HRGN Revenue
Harvard Apparatus Regenerative Technology had revenue of $414.00K in the quarter ending June 30, 2026, with 30.60% growth. This brings the company's revenue in the last twelve months to $982.00K, up 44.62% year-over-year. In the year 2025, Harvard Apparatus Regenerative Technology had annual revenue of $704.00K with 63.72% growth.
Revenue (ttm)
982.00K
Revenue Growth
+44.62%
P/S Ratio
42.07
Revenue / Employee
122.75K
Employees
8
Market Cap
41.31M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 704.00K | 274.00K | 63.72% |
| Dec 31, 2024 | 430.00K | 327.00K | 317.48% |
| Dec 31, 2023 | 103.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Hanover Foods | 330.81M |
| Elamex SA de CV | 110.74M |
| DAVIDsTEA | 44.42M |
| Starco Brands | 35.93M |
| Glucose Health | 1.11M |
| UMeWorld | 1.04M |
| Limitless X Holdings | 511.81K |
| China Foods Holdings | 185.87K |
Harvard Apparatus Regenerative Technology News
- 22 days ago - Harvard Apparatus Regenerative Technology Quarterly report: Q2 2026 - Filings
- 3 months ago - Harvard Apparatus Regenerative Technology Quarterly report: Q1 2026 - Filings
- 4 months ago - Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic - GlobeNewsWire
- 4 months ago - Harvard Apparatus Regenerative Technology Proxy statement: Proxy filing - Filings
- 5 months ago - Harvard Apparatus Regenerative Technology Annual report: Q4 2025 - Filings
- 7 months ago - Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease - GlobeNewsWire
- 10 months ago - Harvard Apparatus Regenerative Technology Quarterly report: Q3 2025 - Filings
- 1 year ago - Harvard Apparatus Regenerative Technology Quarterly report: Q2 2025 - Filings